Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.

Article  CAS  PubMed  Google Scholar 

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95:691–709.

Article  CAS  PubMed  Google Scholar 

Sasaki K, Strom SS, O’Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015;2:e186–93.

Article  PubMed  PubMed Central  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34:2333–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffmann VS, Baccarani M, Hasford J, et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia. 2017;31:593–601.

Article  CAS  PubMed  Google Scholar 

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.

Article  PubMed  Google Scholar 

• Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017;123:4391–402. Retrospective analysis identifying prognostic factors in patients with CML-BP.

Article  CAS  PubMed  Google Scholar 

Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023;37:5–17.

Article  PubMed  Google Scholar 

Giles FJ, Cortes JE, Kantarjian HM, O’Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:753–74.

Article  PubMed  Google Scholar 

•• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84. The European LeukemiaNet recommendations on CML, which include definitions of CML-AP and CML-BP.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. The WHO 2020 recommendations that removed the category of CML-AP and replaced it with “high-risk CML.

Article  PubMed  PubMed Central  Google Scholar 

Wang W, Chen Z, Hu Z, et al. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia. Blood Cancer J. 2016;6:e490-e.

Article  Google Scholar 

Issa GC, Kantarjian HM, Gonzalez GN, et al. Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatment. Blood. 2017;130:2084–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Senapati J, Sasaki K. Chromosomal instability in chronic myeloid leukemia: mechanistic insights and effects. Cancers. 2022;14:2533.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5:1102–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bataller A, Sasaki K, Jabbour E, et al. Prognostic model of transformation to blast phase in patients with chronic myeloid leukemia. Blood. 2022;140:3895–6.

Article  Google Scholar 

Hehlmann R, Voskanyan A, Lauseker M, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34:2074–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Cortes JE, Lin P, et al. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood. 2015;126:1699–706.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016;127:2742–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carella AM, Garuti A, Cirmena G, et al. Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. Leuk Lymphoma. 2010;51:275–8.

Article  CAS  PubMed  Google Scholar 

Loy K, Zenger M, Meggendorfer M, et al. Analysis of mechanisms of blast crisis in chronic myeloid leukemia by whole genome sequencing. Blood. 2020;136:19.

Article  Google Scholar 

Machnicki MM, Pepek M, Solarska I, et al. ASXL1 mutations detectable at diagnosis may predict response to imatinib in patients with chronic myeloid leukemia. Blood. 2019;134:4148.

Article  Google Scholar 

Marum JE, Yeung DT, Purins L, et al. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Adv. 2017;1:1369–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Menezes J, Salgado RN, Acquadro F, et al. ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia. Blood Cancer J. 2013;3:e157-e.

Article  Google Scholar 

Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005;23:4100–9.

Article  CAS  PubMed  Google Scholar 

Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132:948–61.

Article  CAS  PubMed  Google Scholar 

Lee KL, Ko TK, Saw NYL, et al. Validation and refinement of a RUNX1 mutation-associated gene expression signature in blast crisis chronic myeloid leukemia. Leukemia. 2022;36:892–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adnan-Awad S, Kim D, Hohtari H, et al. Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia. 2021;35:1964–75.

Article  CAS  PubMed  Google Scholar 

Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009;114:2232–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117:3733–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lauseker M, Hasford J, Saussele S, et al. Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death. Cancer. 2017;123:2467–71.

Article  CAS  PubMed  Google Scholar 

Ohanian M, Kantarjian HM, Shoukier M, et al. The clinical impact of time to response in de novo accelerated-phase chronic myeloid leukemia. Am J Hematol. 2020;95:1127–34.

Article  CAS